Cellectis publishes TALE-based epigenetic modulator screening presentation

• Cellectis published an ASGCT 2026 poster describing a high-throughput multiplex screening platform for TALE-based epigenetic modulators designed to deliver durable gene knockdown without double-strand DNA breaks.
• Proof-of-concept work showed roughly 10-fold, sustained target protein reduction in primary T-cells for at least 29 days, with CpG methylation reaching about 90% at sites unmethylated in mock-treated cells.
• In HepG2 cells, subset of multiplex groups produced up to about 10-fold reduction in secreted target protein for at least 49 days, supporting potential in-vivo and T-cell engineering applications.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cellectis SA published the original content used to generate this news brief on May 13, 2026, and is solely responsible for the information contained therein.